ABL Bio Inc. (KOSDAQ: 298380), a biotechnology company specializing in bispecific antibodies for immuno-oncology and neurodegenerative diseases, has announced a global licensing agreement with pharmaceutical
ABL Bio Inc. (KOSDAQ: 298380), a biotechnology company specializing in bispecific antibodies for immuno-oncology and neurodegenerative diseases, has announced a global licensing agreement with pharmaceutical